175 related articles for article (PubMed ID: 9397194)
1. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma.
Bander NH; Yao D; Liu H; Chen YT; Steiner M; Zuccaro W; Moy P
Prostate; 1997 Dec; 33(4):233-9. PubMed ID: 9397194
[TBL] [Abstract][Full Text] [Related]
2. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
3. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro.
Akbasak A; Oldfield EH; Saris SC
J Neurosurg; 1991 Dec; 75(6):922-9. PubMed ID: 1941122
[TBL] [Abstract][Full Text] [Related]
4. Regulation of major histocompatibility gene expression in human vascular smooth muscle cells.
Warner SJ; Friedman GB; Libby P
Arteriosclerosis; 1989; 9(3):279-88. PubMed ID: 2470342
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
6. HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF.
Beniers AJ; Peelen WP; Debruyne FM; Schalken JA
Int J Cancer; 1991 Jul; 48(5):709-16. PubMed ID: 1906431
[TBL] [Abstract][Full Text] [Related]
7. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of defective antigen processing in human prostate cancer.
Sanda MG; Restifo NP; Walsh JC; Kawakami Y; Nelson WG; Pardoll DM; Simons JW
J Natl Cancer Inst; 1995 Feb; 87(4):280-5. PubMed ID: 7707419
[TBL] [Abstract][Full Text] [Related]
9. Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium.
Sharpe JC; Abel PD; Gilbertson JA; Brawn P; Foster CS
Br J Urol; 1994 Nov; 74(5):609-16. PubMed ID: 7530126
[TBL] [Abstract][Full Text] [Related]
10. Comparative assessment of MHC antigen expression in bladder and testis tumour biopsies and established urological tumour cell lines: the relevance of cytokine and gene transfection for correction of defective MHC antigens.
Nouri AM; Symes MO
Oncol Rep; 2000; 7(5):959-64. PubMed ID: 10948322
[TBL] [Abstract][Full Text] [Related]
11. The frequency of major histocompatibility complex antigen abnormalities in urological tumours and their correction by gene transfection or cytokine stimulation.
Nouri AM; Hussain RF; Oliver RT
Cancer Gene Ther; 1994 Jun; 1(2):119-23. PubMed ID: 7621243
[TBL] [Abstract][Full Text] [Related]
12. Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines.
Jabrane-Ferrat N; Faille A; Loiseau P; Poirier O; Charron D; Calvo F
Int J Cancer; 1990 Jun; 45(6):1169-76. PubMed ID: 2112515
[TBL] [Abstract][Full Text] [Related]
13. Class I and class II major histocompatibility complex antigens expression on human hepatocytes and hepatoma cells: an approach with high sensitivity and specificity.
Chiu JH; Lui WY; Chang HM; Loong CC; Wu LH; Kao HL; Wu CW
Cytometry; 1997 Dec; 30(6):317-23. PubMed ID: 9440824
[TBL] [Abstract][Full Text] [Related]
14. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.
Ritter M; Huber C; Auböck J; Pohl-Markl H; Troppmair J; Herold M; Gächter A; Nussbaumer W; Böck G; Nachbaur D
Immunology; 1994 Apr; 81(4):569-77. PubMed ID: 7913694
[TBL] [Abstract][Full Text] [Related]
15. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells.
Maio M; Gulwani B; Morgano A; Ferrone S
Int J Cancer; 1989 Sep; 44(3):554-9. PubMed ID: 2506138
[TBL] [Abstract][Full Text] [Related]
16. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
17. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.
Yang I; Kremen TJ; Giovannone AJ; Paik E; Odesa SK; Prins RM; Liau LM
J Neurosurg; 2004 Feb; 100(2):310-9. PubMed ID: 15086239
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells.
Nisticò P; Tecce R; Giacomini P; Cavallari A; D'Agnano I; Fisher PB; Natali PG
Cancer Res; 1990 Dec; 50(23):7422-9. PubMed ID: 1701342
[TBL] [Abstract][Full Text] [Related]
19. Accurate and rapid assessment of MHC antigen upregulation following cytokine stimulation.
Gillott DJ; Nouri AM; Compton SJ; Oliver RT
J Immunol Methods; 1993 Oct; 165(2):231-9. PubMed ID: 8228273
[TBL] [Abstract][Full Text] [Related]
20. Regulation of MHC expression in vivo. II. IFN-alpha/beta inducers and recombinant IFN-alpha modulate MHC antigen expression in mouse tissues.
Halloran PF; Urmson J; Van der Meide PH; Autenried P
J Immunol; 1989 Jun; 142(12):4241-7. PubMed ID: 2498428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
